Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9537605 | 0.77 | MAPK1 (0.61) | MAPK1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL27218042 | 0.76 | MAPK1 (0.41) | MAPK1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL27218084 | 0.75 | MAPK1 (0.40) | MAPK1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL25529240 | 0.75 | ALDH1A1 (0.39) | MAPK1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL25529232 | 0.74 | SMN1; SMN2 (0.44) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL25533295 | 0.67 | KDM4E (0.58) | MAPK1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL25529231 | 0.65 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL25536925 | 0.62 | KMT2A (0.47) | MAPK1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29867991 | 0.60 | ALDH1A1 (0.34) | MAPK1ALDH1A1POLBKDM4E | |
| SCHEMBL15968716 | 0.59 | ALDH1A1 (0.44) | MAPK1MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4110779-A1 | COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | MAPK1 310/4885MEN1 3817/4885KMT2A 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.